JP7176767B2 - 新規なアモジアキン類似体およびその使用方法 - Google Patents

新規なアモジアキン類似体およびその使用方法 Download PDF

Info

Publication number
JP7176767B2
JP7176767B2 JP2019556272A JP2019556272A JP7176767B2 JP 7176767 B2 JP7176767 B2 JP 7176767B2 JP 2019556272 A JP2019556272 A JP 2019556272A JP 2019556272 A JP2019556272 A JP 2019556272A JP 7176767 B2 JP7176767 B2 JP 7176767B2
Authority
JP
Japan
Prior art keywords
compound
quinoline
mmol
formula
ylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019556272A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517603A5 (https=
JP2020517603A (ja
Inventor
ロバート エイ デイヴィー
康晃 櫻井
昌範 馬場
紀和 榊原
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kagoshima University NUC
Original Assignee
Kagoshima University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kagoshima University NUC filed Critical Kagoshima University NUC
Publication of JP2020517603A publication Critical patent/JP2020517603A/ja
Publication of JP2020517603A5 publication Critical patent/JP2020517603A5/ja
Application granted granted Critical
Publication of JP7176767B2 publication Critical patent/JP7176767B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019556272A 2017-04-13 2018-04-13 新規なアモジアキン類似体およびその使用方法 Active JP7176767B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762485273P 2017-04-13 2017-04-13
US62/485,273 2017-04-13
PCT/US2018/027528 WO2018191642A1 (en) 2017-04-13 2018-04-13 Novel amodiaquine analogs and methods of uses thereof

Publications (3)

Publication Number Publication Date
JP2020517603A JP2020517603A (ja) 2020-06-18
JP2020517603A5 JP2020517603A5 (https=) 2021-05-27
JP7176767B2 true JP7176767B2 (ja) 2022-11-22

Family

ID=63792882

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019556272A Active JP7176767B2 (ja) 2017-04-13 2018-04-13 新規なアモジアキン類似体およびその使用方法

Country Status (3)

Country Link
US (1) US11571416B2 (https=)
JP (1) JP7176767B2 (https=)
WO (1) WO2018191642A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110214011A (zh) 2017-01-19 2019-09-06 国立大学法人鹿儿岛大学 抗严重发热伴血小板减少综合征病毒的药物
WO2021235390A1 (ja) * 2020-05-18 2021-11-25 国立大学法人鹿児島大学 抗ＳＡＲＳ－ＣｏＶ－２薬
EP3960176A1 (en) * 2020-08-26 2022-03-02 DMG Deutsche Malaria GmbH Piperaquine and related drug combinations for use in the treatment of covid-19
JPWO2023085392A1 (https=) 2021-11-12 2023-05-19

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013138200A1 (en) 2012-03-13 2013-09-19 Howard University Green chemistry synthesis of the malaria drug amodiaquine and analogs thereof
WO2018135449A1 (ja) 2017-01-19 2018-07-26 国立大学法人鹿児島大学 抗重症熱性血小板減少症候群ウイルス薬

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060142259A1 (en) * 2004-06-25 2006-06-29 Limin Li Compounds, pharmaceutical compositions and methods for inhibiting HIV infectivity
WO2007098047A2 (en) * 2006-02-16 2007-08-30 The Mclean Hospital Corporation Methods and compositions for the treatment of parkinson's disease
CN104703601A (zh) * 2012-07-03 2015-06-10 格雷斯兰生物科技股份有限公司 用于治疗和抑制病毒感染的组合物和方法
US20140011837A1 (en) * 2012-07-03 2014-01-09 Justice E. OBI Compositions and methods for treating warts associated with viral infections
AU2015214176A1 (en) * 2014-02-06 2016-09-15 Georgetown University Treating Flavivirus infections with amodiaquine and derivatives thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013138200A1 (en) 2012-03-13 2013-09-19 Howard University Green chemistry synthesis of the malaria drug amodiaquine and analogs thereof
WO2018135449A1 (ja) 2017-01-19 2018-07-26 国立大学法人鹿児島大学 抗重症熱性血小板減少症候群ウイルス薬

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCIENTIFIC REPORTS，2015年，Vol.5:13476，p.1-13

Also Published As

Publication number Publication date
WO2018191642A1 (en) 2018-10-18
JP2020517603A (ja) 2020-06-18
US11571416B2 (en) 2023-02-07
US20200113891A1 (en) 2020-04-16

Similar Documents

Publication Publication Date Title
JP7176767B2 (ja) 新規なアモジアキン類似体およびその使用方法
JP2650045B2 (ja) 新規な抗抑欝剤
JP2025134881A (ja) Ｓａｒｓの治療のための化合物
EP2447253A1 (en) Dihydropyrimidine compounds and preparation methods, pharmaceutical compositions and uses thereof
TWI453201B (zh) 可作為Hsp90之抑制劑之異吲哚衍生物
US11001557B2 (en) Antiviral drug for severe fever with thrombocytopenia syndrome
EP4255401A1 (en) Compounds for the treatment of sars
CN114867531A (zh) Egfr抑制剂
WO2020191205A1 (en) Pi4-kinase inhibitors and methods of using the same
RU2436786C1 (ru) Замещенные индолы, противовирусный активный компонент, способ получения и применения
US8048889B2 (en) 3,4-disubstituted coumarin and quinolone compounds
JP2022509763A (ja) アレナウイルス感染症の治療のための化合物
CN111393377B (zh) 具有抗癌作用的氘代嘧啶衍生物
WO2017121188A1 (zh) 一种丙型肝炎病毒抑制剂、药物组合物及其应用
WO2010062221A1 (ru) Замещенные 2-(5-гидpokcи-2-metил-1н-иhдoл-3-ил)уkcуchыe кислоты и их эфиры и их применение для лечения вирусных заболеваний
CN114591322A (zh) 炔基吡啶类化合物，其药物组合物、制备方法和应用
CN110234317A (zh) 具有治疗与非酒精性脂肪性肝炎(nash)和高甘油三酯血症相关的肥胖的双重作用的依拉贝特二甲双胍盐
CN116419753A (zh) 作为bcl-2抑制剂的杂环化合物
JP7711088B2 (ja) Ｓａｒｓの治療のための化合物
KR102881036B1 (ko) 벤즈이미다졸 유도체를 유효 성분으로 포함하는 인터페론 유전자 자극제 조성물
HK40079554A (en) Egfr inhibitors
HK40122606A (zh) 吲唑吡啶酮化合物及其用途
CN102112461B (zh) 新型二芳基庚酮系化合物及其应用
HK40057712B (zh) 含有n杂五元环的衣壳蛋白装配抑制剂、其药物组合物和用途
HK40067856A (en) Quinazoline prodrugs for the treatment of viral infections and further diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210412

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220124

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220623

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220707

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221004

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221019

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221102

R150 Certificate of patent or registration of utility model

Ref document number: 7176767

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250